Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NBRV Stock Summary
In the News
7 Stocks to Sell as Banks Melt Down
Peruse the Internet for investment guidance and you're likely to hear the adage that you shouldn't consider stocks to sell when faced with volatility. Rather, you should buy up assets and securities when there's blood on the streets.
Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study
Nabriva (NBRV) posts positive top-line data from the phase I study evaluating oral and intravenous Xenleta (lefamulin) in adult patients with cystic fibrosis. Shares down.
Nabriva's stock is up after sharing antibiotic news
Shares of Nabriva Therapeutics Plc NBRV, were up 13.8% in premarket trading on Monday after the company said in a news release it had positive data from a Phase 1 clinical trial assessing its antibiotic as a treatment for cystic fibrosis. The drug, Xenleta, is approved to treat community-acquired bacterial pneumonia.
Nabriva Therapeutics plc (NBRV) Q3 2022 Earnings Call Transcript
Nabriva Therapeutics plc (NASDAQ:NBRV ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Daniel Dolan - CFO Theodore Schroeder - CEO Conference Call Participants Carl Byrnes - Northland Capital Markets Ed Arce - H.C. Wainwright Operator Welcome to the Nabriva Therapeutics Third Quarter 2022 Financial Results Call and Corporate Update.
Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022
DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, November 10, 2022. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights.
What Is Going on With Nabriva Therapeutics (NBRV) Stock Today?
Source: iQoncept / Shutterstock Nabriva Therapeutics (NASDAQ: NBRV ) stock caught the attention of traders on Friday after shares surged in price this morning. However, not all is as it seems.
Buying Penny Stocks Today? What You Need to Know
Here's what you need to know about trading penny stocks on September 16th The post Buying Penny Stocks Today? What You Need to Know appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Nabriva Therapeutics (NBRV) Stock: 1-For-25 Reverse Stock Split Announced
Nabriva Therapeutics (NBRV) announces it will effect a 1-for-25 reverse stock split. These are the details.
Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split
DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will effect a 1-for-25 reverse stock split of its outstanding ordinary shares, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on September 16, 2022.
All You Need to Know About Nabriva Therapeutics AG (NBRV) Rating Upgrade to Buy
Nabriva Therapeutics AG (NBRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NBRV Financial details
NBRV Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 31.99 | 26.11 | 5.57 | 15.7 | 13.3 | |
Net income per share | -564.91 | -278.86 | -135.23 | -28.52 | -21.32 | |
Operating cash flow per share | -357.92 | -242.23 | -138.83 | -34.35 | -13.69 | |
Free cash flow per share | -359.05 | -242.43 | -139.05 | -34.36 | -13.77 | |
Cash per share | 503.13 | 290.41 | 80.53 | 27.49 | 4.63 | |
Book value per share | 337.77 | 139.06 | 64.49 | 30.77 | 1.23 | |
Tangible book value per share | 337.29 | 138.76 | 64.33 | 30.75 | 1.23 | |
Share holders equity per share | 337.77 | 139.06 | 64.49 | 30.77 | 1.23 | |
Interest debt per share | 117.39 | 128.53 | 18.42 | 4.11 | 2.21 | |
Market cap | 74.16M | 97.94M | 31.09M | 25.96M | 5.07M | |
Enterprise value | -4.12M | 46.43M | -2.55M | -13.67M | -2.12M | |
P/E ratio | -0.65 | -1.18 | -0.45 | -0.53 | -0.09 | |
Price to sales ratio | 11.41 | 12.64 | 10.85 | 0.95 | 0.14 | |
POCF ratio | -1.02 | -1.36 | -0.44 | -0.44 | -0.14 | |
PFCF ratio | -1.02 | -1.36 | -0.44 | -0.44 | -0.14 | |
P/B Ratio | 1.08 | 2.37 | 0.94 | 0.49 | 1.54 | |
PTB ratio | 1.08 | 2.37 | 0.94 | 0.49 | 1.54 | |
EV to sales | -0.63 | 5.99 | -0.89 | -0.5 | -0.06 | |
Enterprise value over EBITDA | 0.04 | -0.59 | 0.04 | 0.28 | 0.04 | |
EV to operating cash flow | 0.06 | -0.65 | 0.04 | 0.23 | 0.06 | |
EV to free cash flow | 0.06 | -0.65 | 0.04 | 0.23 | 0.06 | |
Earnings yield | -1.55 | -0.85 | -2.24 | -1.9 | -11.28 | |
Free cash flow yield | -0.98 | -0.73 | -2.3 | -2.29 | -7.28 | |
Debt to equity | 0.35 | 0.84 | 0.23 | 0.15 | 1.59 | |
Debt to assets | 0.21 | 0.37 | 0.13 | 0.1 | 0.16 | |
Net debt to EBITDA | 0.69 | 0.65 | 0.52 | 0.82 | 0.13 | |
Current ratio | 6.11 | 5.48 | 3.09 | 3.59 | 1.13 | |
Interest coverage | -859.96 | -21.81 | -38.11 | 53.86 | -73.31 | |
Income quality | 0.63 | 0.87 | 1.03 | 1.2 | 0.64 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 6.42 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 12.66 | 3.41 | 5.27 | 0.46 | 0.4 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0.01 | |
Capex to revenue | -0.04 | -0.01 | -0.04 | 0 | -0.01 | |
Capex to depreciation | -0.45 | -0.08 | -0.14 | -0.04 | -0.97 | |
Stock based compensation to revenue | 0.79 | 1.26 | 1.82 | 0.12 | 0.06 | |
Graham number | 2.07K | 934.09 | 442.98 | 140.51 | 24.27 | |
ROIC | -1.24 | -1.05 | -1.62 | -0.8 | -6.18 | |
Return on tangible assets | -1.04 | -0.88 | -1.19 | -0.61 | -1.8 | |
Graham Net | 317.29 | 120.47 | 42.66 | 21.3 | -2.3 | |
Working capital | 90.95M | 74.53M | 38.69M | 57.93M | 3.5M | |
Tangible asset value | 68.53M | 41.18M | 33.06M | 53.32M | 3.29M | |
Net current asset value | 66.97M | 38.33M | 31.92M | 52.71M | 2.63M | |
Invested capital | 0.35 | 0.84 | 0.23 | 0.15 | 1.59 | |
Average receivables | 5.39M | 4.06M | 3.33M | 8.33M | 9.75M | |
Average payables | 4.22M | 3.99M | 3.78M | 3.63M | 4.9M | |
Average inventory | 0 | 341K | 3.25M | 10.17M | 12.09M | |
Days sales outstanding | 301.6 | 129.27 | 498.18 | 171.01 | 68.99 | |
Days payables outstanding | 0 | 24.37K | 1.38K | 121.37 | 69.36 | |
Days of inventory on hand | 0 | 3.56K | 2.77K | 402.78 | 123.57 | |
Receivables turnover | 1.21 | 2.82 | 0.73 | 2.13 | 5.29 | |
Payables turnover | 0 | 0.01 | 0.27 | 3.01 | 5.26 | |
Inventory turnover | 0 | 0.1 | 0.13 | 0.91 | 2.95 | |
ROE | -1.67 | -2.01 | -2.1 | -0.93 | -17.37 | |
Capex per share | -1.13 | -0.21 | -0.22 | -0.01 | -0.08 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 3.26 | 3.47 | 3.21 | 3.89 | 2.37 | |
Net income per share | -5.03 | -4.38 | -4.21 | -8.49 | -2.85 | |
Operating cash flow per share | -6.75 | -5.15 | -2.26 | -0.61 | -1.75 | |
Free cash flow per share | -6.76 | -5.18 | -2.3 | -0.61 | -1.76 | |
Cash per share | 14.37 | 7.92 | 5.36 | 4.63 | 0.56 | |
Book value per share | 18.98 | 13.68 | 9.38 | 1.23 | -1.36 | |
Tangible book value per share | 18.97 | 13.68 | 9.37 | 1.23 | -1.36 | |
Share holders equity per share | 18.98 | 13.68 | 9.38 | 1.23 | -1.36 | |
Interest debt per share | 3.54 | 2.9 | 2.3 | 2 | 0.23 | |
Market cap | 24.69M | 11.51M | 5.68M | 5.07M | 5.59M | |
Enterprise value | -977.47K | -1.4M | -2.83M | -2.12M | 4.34M | |
P/E ratio | -0.52 | -0.26 | -0.12 | -0.06 | -0.15 | |
Price to sales ratio | 3.22 | 1.31 | 0.65 | 0.49 | 0.74 | |
POCF ratio | -1.56 | -0.88 | -0.92 | -3.12 | -1 | |
PFCF ratio | -1.55 | -0.88 | -0.91 | -3.1 | -0.99 | |
P/B Ratio | 0.55 | 0.33 | 0.22 | 1.54 | -1.28 | |
PTB ratio | 0.55 | 0.33 | 0.22 | 1.54 | -1.28 | |
EV to sales | -0.13 | -0.16 | -0.32 | -0.2 | 0.57 | |
Enterprise value over EBITDA | 0.09 | 0.13 | 0.26 | 0.1 | -0.51 | |
EV to operating cash flow | 0.06 | 0.11 | 0.46 | 1.31 | -0.77 | |
EV to free cash flow | 0.06 | 0.11 | 0.45 | 1.3 | -0.77 | |
Earnings yield | -0.48 | -0.96 | -2.03 | -4.49 | -1.63 | |
Free cash flow yield | -0.64 | -1.14 | -1.1 | -0.32 | -1.01 | |
Debt to equity | 0.18 | 0.21 | 0.24 | 1.59 | -0.12 | |
Debt to assets | 0.12 | 0.13 | 0.13 | 0.16 | 0.02 | |
Net debt to EBITDA | 2.3 | 1.24 | 0.79 | 0.32 | 0.15 | |
Current ratio | 4.01 | 2.81 | 2.2 | 1.13 | 0.85 | |
Interest coverage | -53.76 | -52.52 | -76.73 | -160.65 | -43.69 | |
Income quality | 1.34 | 1.18 | 0.54 | 0.07 | 0.65 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.46 | 0.47 | 0.46 | 0.25 | 0.35 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0.02 | 0.01 | 0 | |
Capex to revenue | 0 | -0.01 | -0.01 | 0 | 0 | |
Capex to depreciation | -0.45 | -0.83 | -2.78 | -0.36 | -0.14 | |
Stock based compensation to revenue | 0.13 | 0.04 | 0.06 | 0.01 | 0.13 | |
Graham number | 46.32 | 36.71 | 29.81 | 15.32 | 9.34 | |
ROIC | -0.23 | -0.26 | -0.37 | -2.66 | 2.33 | |
Return on tangible assets | -0.18 | -0.2 | -0.24 | -0.72 | -0.37 | |
Graham Net | 12.2 | 6.64 | 3.65 | -2.3 | -4.53 | |
Working capital | 48.93M | 34.96M | 25.92M | 3.5M | -4.3M | |
Tangible asset value | 44.6M | 34.59M | 25.62M | 3.29M | -4.36M | |
Net current asset value | 44.04M | 34.01M | 24.95M | 2.63M | -5M | |
Invested capital | 0.18 | 0.21 | 0.24 | 1.59 | -0.12 | |
Average receivables | 11.88M | 11.68M | 12.37M | 9.57M | 8.63M | |
Average payables | 2.98M | 1.33M | 2.48M | 4.66M | 6.2M | |
Average inventory | 15.07M | 15.58M | 16.43M | 13.5M | 9.35M | |
Days sales outstanding | 129.17 | 126.77 | 126.93 | 58.13 | 124.62 | |
Days payables outstanding | 42.26 | 21.68 | 79.38 | 29.9 | 141.51 | |
Days of inventory on hand | 418.59 | 313.84 | 353.25 | 53.27 | 183.06 | |
Receivables turnover | 0.7 | 0.71 | 0.71 | 1.55 | 0.72 | |
Payables turnover | 2.13 | 4.15 | 1.13 | 3.01 | 0.64 | |
Inventory turnover | 0.22 | 0.29 | 0.25 | 1.69 | 0.49 | |
ROE | -0.26 | -0.32 | -0.45 | -6.92 | 2.09 | |
Capex per share | -0.01 | -0.03 | -0.04 | 0 | 0 |
NBRV Frequently Asked Questions
What is Nabriva Therapeutics plc stock symbol ?
Nabriva Therapeutics plc is a IE stock and trading under the symbol NBRV
Is Nabriva Therapeutics plc buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $1. The lowest prediction is $1 and the highest is $1
What is NBRV stock prediction ?
What is Nabriva Therapeutics plc stock quote today ?
Nabriva Therapeutics plc stock price is $- today.
Is Nabriva Therapeutics plc stock public?
Yes, Nabriva Therapeutics plc is a publicly traded company.